Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma

Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma

Endometrial cancer is one of the most common gynaecological cancers in both the United States and the Russian Federation, and the rate continues to rise. Although early-stage endometrial cancer is associated with a favourable 5-year survival rate (96%), this rate in patients with distant metastases...

Full description

Saved in:
Bibliographic Details
Main Authors: K. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, I. A. Menshikova, N. I. Sultanbaeva, A. A. Izmailov, A. A. Fatikhova, D. O. Lipatov, G. A. Serebrennikov
Format: Article
Language:English
Published: Bashkir State Medical University 2023-01-01
Series:Креативная хирургия и онкология
Subjects:
endometrial carcinoma
microsatellite instability
immunotherapy
chemotherapy
tyrosine kinase inhibitors
lenvatinib
pembrolizumab
Online Access:https://www.surgonco.ru/jour/article/view/738
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.surgonco.ru/jour/article/view/738

Similar Items